Completed PHASE1 INTERVENTIONAL 1-arm NCT03216343

Phase Ib/II Study of Chiauranib in Patients With Small Cell Lung Cancer

Efficacy and Safety of Chiauranib in Relapsed/Refractory Small Cell Lung Cancer: a Single-arm, Open-label, Multi-center, Exploratory Phase Ib Study

Sponsor: Chipscreen Biosciences, Ltd.

Conditions Small Cell Lung Cancer

Interventions Chiauranib

Updated 11 times since 2017 Last updated: Aug 28, 2023 Started: Nov 9, 2017 Primary completion: Nov 4, 2022 Completion: May 15, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Small Cell Lung Cancer, this trial is completed. The trial is conducted by Chipscreen Biosciences, Ltd. and has accumulated 11 data snapshots since 2017. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

11 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Sep 2023 — Jul 2024 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Apr 2022 — Sep 2023 [monthly]

Recruiting PHASE1

Status: Unknown Status → Recruiting
Oct 2021 — Apr 2022 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status

▶ Show 6 earlier versions

Jan 2021 — Oct 2021 [monthly]

Recruiting PHASE1
Aug 2019 — Jan 2021 [monthly]

Recruiting PHASE1
Feb 2019 — Aug 2019 [monthly]

Recruiting PHASE1
Jun 2018 — Feb 2019 [monthly]

Recruiting PHASE1
Dec 2017 — Jun 2018 [monthly]

Recruiting PHASE1

Status: Not Yet Recruiting → Recruiting
Aug 2017 — Dec 2017 [monthly]

Not Yet Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chipscreen Biosciences, Ltd.

Data source: Chipscreen Biosciences, Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China